The vast majority of panel members consider the assessment of MSI and HER2 as essential for all patients before treatment initiation, with division of opinions about other markers, such as tumor mutational burden, p53, PD-L1, POLE, and hormone receptors (Table 1). Here, NR4A1 is linked to neoplasm.